The efficacy of the 2005/2006 influenza season vaccine was assessed, which consisted of A/H1N1/New Caledonia/20/99, A/H3N2/New York/55/2004 and B/Shanghai/361/2002, in healthcare workers, by determining the hemagglutination-inhibition (HI) antibody titer against each vaccine strain. The seroprotection rates (ratio of subjects with a protective HI antibody titer of 40 or higher) of the 2004/2005 season vaccine employed against A/H1N1/New Caledonia, A/H3N2/New York, B/Shanghai and A/H3N2/Wyoming were 65.0%, 32.5%, 48.4% and 42.0%, respectively, before the vaccination, and increased to 92.2%, 95.7%, 76.6% and 86.5%, respectively, 4weeks after immunization. Significantly (p< 0.001) higher increases in antibody titer were observed in subjects without protective HI antibody than in subjects with protective HI antibody. The seroprotection rates against A/H1N1/New Caledonia, A/H3N2/New York, B/Shanghai and A/H3N2/Wyoming, were decreased to 89.6%, 88.1%, 70.1%, and 86.6%, respectively, at 16 weeks after vaccination, and then to 67.2%, 62.5%, 57.8% and 50.0%, respectively, at 1 year after vaccination. HI antibody titers against all strains except for A/H1N1/New Caledonia persisted at higher ratios at 1 year after vaccination than before vaccination. Of 11 subjects in the non-vaccinated group, none was diagnosed with influenza, yet 4 showed a 4-fold or more increase in antibody titer, indicating the presence of silent infection. Since no subject in the vaccinated group was diagnosed with influenza during this season, we were not able to assess the protective effect of the vaccination. Differences in antibody titers before vaccination were evident in the A/H3N2, Wyoming and New York strains, so annual vaccination is recommended.
View full abstract